Tower Research Capital (TRC)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,654
| Closed | -$5.81K | – | 6174 |
|
|
2024
Q1 | $5.81K | Sell |
3,654
-8,028
| -69% | -$12.8K | ﹤0.01% | 4484 |
|
|
2023
Q4 | $10K | Sell |
11,682
-16,216
| -58% | -$13.9K | ﹤0.01% | 4306 |
|
|
2023
Q3 | $29.9K | Buy |
27,898
+23,850
| +589% | +$25.5K | ﹤0.01% | 3027 |
|
|
2023
Q2 | $10.5K | Sell |
4,048
-723
| -15% | -$1.87K | ﹤0.01% | 4090 |
|
|
2023
Q1 | $19K | Buy |
4,771
+1,719
| +56% | +$6.85K | ﹤0.01% | 3521 |
|
|
2022
Q4 | $16K | Sell |
3,052
-2,622
| -46% | -$13.7K | ﹤0.01% | 3390 |
|
|
2022
Q3 | $74K | Buy |
5,674
+3,441
| +154% | +$44.9K | ﹤0.01% | 2832 |
|
|
2022
Q2 | $29K | Buy |
2,233
+1,218
| +120% | +$15.8K | ﹤0.01% | 3426 |
|
|
2022
Q1 | $16K | Buy |
1,015
+279
| +38% | +$4.4K | ﹤0.01% | 3775 |
|
|
2021
Q4 | $13K | Sell |
736
-5,499
| -88% | -$97.1K | ﹤0.01% | 4223 |
|
|
2021
Q3 | $131K | Buy |
6,235
+3,442
| +123% | +$72.3K | ﹤0.01% | 2171 |
|
|
2021
Q2 | $55K | Buy |
2,793
+1,091
| +64% | +$21.5K | ﹤0.01% | 2957 |
|
|
2021
Q1 | $49K | Buy |
1,702
+465
| +38% | +$13.4K | ﹤0.01% | 3151 |
|
|
2020
Q4 | $37K | Sell |
1,237
-4,953
| -80% | -$148K | ﹤0.01% | 3407 |
|
|
2020
Q3 | $98K | Buy |
6,190
+2,276
| +58% | +$36K | ﹤0.01% | 3162 |
|
|
2020
Q2 | $77K | Buy |
3,914
+2,590
| +196% | +$51K | ﹤0.01% | 2694 |
|
|
2020
Q1 | $16K | Buy |
+1,324
| New | +$16K | ﹤0.01% | 1831 |
|
|
2019
Q3 | – | Sell |
-1,072
| Closed | -$16K | – | 4622 |
|
|
2019
Q2 | $16K | Buy |
+1,072
| New | +$16K | ﹤0.01% | 2311 |
|